Hemodialysis does not affect everolimus pharmacokinetics: Two cases of patients with metastatic renal cell cancer

Annals of Oncology

Volumn 23, Issue 11, 2012, Pages 2992-2993

  Thiery Vuillemin, A ^a,b,c   Curtit, E ^c   Maurina, T ^c   Montange, D ^c   Succi, C ^d   Guyen, T N ^c   Kim, S ^c   Montcuquet, P ^c   Pivot, X ^a,b,c   Royer, B ^a,c  

^a INSERM   (France)

^b UNIVERSITÉ DE FRANCHE COMTÉ   (France)

^c UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

^d Immuno Molec Therapeut Laboratory   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84868139593     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds477     Document Type: Letter

References (2)

1. Motzer RJ, Escudier B, Oudard S et al. RECORD-1 Study Group. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 2010; 116(18): 4256-4265.
2. Bogusz MJ, Enazi EA, Hassan H et al. Simultaneous LC-MS-MS determination of cyclosporine A, tacrolimus, and sirolimus in whole blood as well as mycophenolic acid in plasma using common pretreatment procedure. J Chromatogr B Analyt Technol Biomed Life Sci 2007; 850(1-2): 471-480.